Prognostic Stage III Breast Cancer AJCC v8 Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Prognostic Stage 3 Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0109635 (Prognostic Stage III Breast Cancer AJCC v8)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerTreatment